Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 18:00 ET | Source: Kane Biotech Inc.

Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results

WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial...
April 23, 2026 15:46 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid...
April 23, 2026 12:40 ET | Source: Regeneron Pharmaceuticals, Inc.

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the...
April 23, 2026 09:00 ET | Source: USA News Group

Florida’s Space Coast Is Becoming a Research Supercluster — And This Supersonic Stock Just Plugged Into the Heart of It

Issued on behalf of Starfighters Space, Inc. Companies mentioned in this commentary include: Starfighters Space, Inc. (NYSE American: FJET), Redwire Corporation (NYSE: RDW), Voyager Technologies...
April 22, 2026 17:30 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...
April 22, 2026 17:30 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with...
April 22, 2026 09:32 ET | Source: Research and Markets

Oilfield Services Market Global Forecast Report 2026-2036: Lucrative Opportunities in New Oilfields, Digital Technology Integration, & Expansion of Deepwater and Unconventional Exploration Activities

Dublin, April 22, 2026 (GLOBE NEWSWIRE) -- The "Oilfield Services Market by Type, Location, and Geography - Global Forecast to 2036" report has been added to ResearchAndMarkets.com's...
April 22, 2026 08:00 ET | Source: Robinhood Markets, Inc.

Robinhood Ventures Fund I (RVI) Announces $75M Investment in OpenAI

Today, Robinhood Ventures Fund I (NYSE: RVI) announced it has closed an investment in OpenAI. On April 17, 2026 RVI purchased approximately $75 million of
April 22, 2026 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand...
April 22, 2026 07:00 ET | Source: NetraMark Holdings Inc.

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company...